Skip to content. | Skip to navigation


Personal tools
 

Sylvia Ng, Ph.D

Peer-Reviewed Papers

 
Peer-Reviewed Papers | Conference Proceedings | Books (and Chapters)

 

        2010

  1. Schaeffer DF, Owen DR, Lim HJ, Buczkowski AK, Chung SW, Scudamore CH, Huntsman DG, Ng SSW, Owen DA. . Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival. BMC Cancer 2010, 10:59 (2010).


    2008

  2. Baker JHE, Lam J, Kyle AH, Sy J, Oliver T, Co S, Dragowska WH, Ramsay E, Anantha M, Ruth TJ, Adam MJ, Yung A, Kozlowski P, Minchinton AI, Ng SSW, Bally MB and Yapp DTT (2008). Irinophore CTM, A Novel Nano-Formulation of Irinotecan, Alters Tumor Vascular Function, and Enhances the Distribution of 5-FU and Doxorubicin Clin Cancer Res 2008 Nov 15:14(22):7260-7l (2008).
    [View Abstract - PubMed 19010842]


    2006

  3. Ng SS, Sparreboom A, Shaked Y, Lee C, Man S, Desai N, Soon-Shiong P, Figg WD, Kerbel RS. Influence of Formulation Vehicle on Metronomic Taxane Chemotherapy: Albumin-Bound versus Cremophor EL-Based Paclitaxel. Clin Cancer Res. 12(14):4331-8. (2006).
    [View Abstract - PubMed 16857808]


    2004

  4. Lepper ER, Ng SS, Gutschow M, Weiss M, Hauschildt S, Hecker TK, Luzzio FA, Eger K, Figg WD. Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors. J Med Chem. 47(9):2219-27. (2004).
    [View Abstract - PubMed 15084120]

  5. McDonald DM, Teicher BA, Stetler-Stevenson W, Ng SS, Figg WD, Folkman J, Hanahan D, Auerbach R, O'Reilly M, Herbst R, Cheresh D, Gordon M, Eggermont A, Libutti SK. Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring. J Immunother. 27(2):161-75. (2004).
    [View Abstract - PubMed 14770088]

  6. Ng SS, Figg WD. Upregulation of endogenous angiogenesis inhibitors: a mechanism of action of metronomic chemotherapy. Cancer Biol Ther. 3(12):1212-3. Epub 2004 Dec 15. (2004).
    [View Abstract - PubMed 15662130]

  7. Ng SS, Figg WD, Sparreboom A. Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins. Cancer Res. 64(3):821-4. (2004).
    [View Abstract - PubMed 14871806]

  8. Ng SS, MacPherson GR, Gutschow M, Eger K, Figg WD. Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice. Clin Cancer Res. 10(12 Pt 1):4192-7. (2004).
    [View Abstract - PubMed 15217957]

  9. Tohnya TM, Ng SS, Dahut WL, Wright JJ, Arlen PM, Gulley JL, Parker C, Zeldis J, Figg WD. A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer. Clin Prostate Cancer. 2(4):241-3. (2004).
    [View Abstract - PubMed 15072608]


    2003

  10. Luzzio FA, Mayorov AV, Ng SS, Kruger EA, Figg WD. Thalidomide metabolites and analogues. 3. Synthesis and antiangiogenic activity of the teratogenic and TNFalpha-modulatory thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine. J Med Chem. 46(18):3793-9. (2003).
    [View Abstract - PubMed 12930142]

  11. Macpherson GR, Ng SS, Forbes SL, Melillo G, Karpova T, McNally J, Conrads TP, Veenstra TD, Martinez A, Cuttitta F, Price DK, Figg WD. Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay. Mol Cancer Ther. 2(9):845-54. (2003).
    [View Abstract - PubMed 14555703]

  12. Ng SS, Figg WD. Antitumor activity of herbal supplements in human prostate cancer xenografts implanted in immunodeficient mice. Anticancer Res. 23(5A):3585-90. (2003).
    [View Abstract - PubMed 14666653]

  13. Ng SS, Gutschow M, Weiss M, Hauschildt S, Teubert U, Hecker TK, Luzzio FA, Kruger EA, Eger K, Figg WD. Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. Cancer Res. 63(12):3189-94. (2003).
    [View Abstract - PubMed 12810647]


    2002

  14. Macpherson GR, Ng SS, Lakhani NJ, Price DK, Venitz J, Figg WD. Antiangiogenesis therapeutic strategies in prostate cancer. Cancer Metastasis Rev. 21(1):93-106. (2002).
    [View Abstract - PubMed 12400998]

  15. Ng SS, Brown M, Figg WD. Thalidomide, an antiangiogenic agent with clinical activity in cancer. Biomed Pharmacother. 56(4):194-9. (2002).
    [View Abstract - PubMed 12109812]

  16. Ng SS, Tsao MS, Nicklee T, Hedley DW. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther. 1(10):777-83. (2002).
    [View Abstract - PubMed 12492110]


    2001

  17. Ng SS, Tsao MS, Nicklee T, Hedley DW. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res. 7(10):3269-75. (2001).
    [View Abstract - PubMed 11595724]


    2000

  18. Ng SS, Pang CC. In vivo venodilator action of fenoldopam, a dopamine D(1)-receptor agonist. Br J Pharmacol. 129(5):853-8. (2000).
    [View Abstract - PubMed 10696081]

  19. Ng SSW, Tsao MS, Chow S, Hedley DW. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res. 60(19):5451-5. (2000).
    [View Abstract - PubMed 11034087]


    1998

  20. Ng, SSW & Pang, CCY (1998).  Zaprinast, a type V phosphodiesterase inhibitor, dilates capacitance vessels in anaesthetised rats.  Eur. J. Pharmacol., 351: 323-328.

  21. Ng, SSW & Pang, CCY (1998).  Venous versus arterial actions of diethylamine/nitric oxide (DEA/NO) complex and S-nitroso-N-acetylpenicillamine (SNAP) in vivo.  Br. J. Pharmacol., 125: 1247-1251.

     

Conference Proceedings

 

Peer-Reviewed Papers | Conference Proceedings | Books (and Chapters)

        2009

  1. Yung, AC, Ng, S, Flexman, J, Tso, JC, Yapp, D, and Kozlowski, P (2009).  Parameter fits using measured population AIF vs. literature AIF in DCE-MRI of pancreatic cancer xenograft model.  Poster presentation at the International Society for Magnetic Resonance in Medicine conference, Honolulu, HI.

  2. Yung, AC, Tso, JC, Flexman, J, Ng, S, Yapp, D, and Kozlowski, P (2009).  Vessel size index and blood volume imaging in pancreatic cancer xenograft model using ferumoxide.  Poster presentation at the International Society for Magnetic Resonance in Medicine conference, Honolulu, HI.

  3. Schaeffer, DF, Owen, D, Lim, HJ, Mehl, E, Buczkowski, AK, Chung, SW, Scudamore, CH, Owen, DA, Ng, SSW, and Hunstman, DG (2009).  Insulin-like growth factor-2 mRNA binding protein 3 (IGF2BP3) expression may be a marker for a unfavorable prognosis in pancreatic ductal adenocarcinoma.  Poster presentation at the United States and Canadian Academy of Pathology annual conference, Boston, MA.


    2008

  4. Flexman, JA, Yung, A, Yapp, DTT, Ng, SSW, and Kozlowski, P (2008).  Assessment of vessel size by magnetic resonance imaging in an orthotopic model of human pancreatic cancer.  Oral presentation at the IEEE Eng Med Biol Soc conference, Vancouver, Canada.  Conf Proc IEEE Eng Med Biol Soc, 851-854.

  5. Cham, KKY, Baker, JH, Takhar, KS, Owen, DA, Yung, A, Kozlowski, P, Buczkowski, AK, Chung, SW, Scudamore, CH, Minchinton, AI, Yapp, DDT, and Ng, SSW (2008).  Metronomic gemcitabine exerts antitumor effects in primary orthotopic human pancreatic cancer xenografts by altering the tumor microenvironment.  Poster Presentation at the AACR conference, San Diego, CA.


    2007

  6. Baker, J, Sy, J, Co, S, Yung, A, Dragowska, W, Ruth, T, Adam, M, Ng, S, Minchinton, A, Kozlowski, P, Ramsay, E, Bally, M, and Yapp, DTT (2007).  Liposomal CPT-11 changes the vasculature and oxygenation status of HT-29 tumours.  Poster Presentation at the 4th International Conference on Tumor Microenvironment: Progression, Therapy, and Prevention, Florence, Italy, March 6-10, 2007.

  7. Cham, KKY, Tai, IT, Takhar, KS., Chu, EM, Owen, DA, Buczkowski, AK, Chung, SW, Scudamore, CH, and Ng, SSW (2007).  Cancer-associated fibroblasts as potential therapeutic targets in pancreatic cancer.  Poster Presentation at the 4th International Conference on Tumor Microenvironment: Progression, Therapy, and Prevention, Florence, Italy, March 6-10, 2007.


    2006

  8. Misri, R., Ng, SSW, and Häfeli, UO (2006).  Molecular bioprobes for imaging malignant mesothelioma.  Poster presentation at the 8th International Conference of the International Mesothelioma Interest Group, Chicago, IL


    2005

  9. Ng, SSW, Sparreboom, A, Shaked, Y, Lee, C, Man, S, Desai, N, Soon-Shiong, P, Figg, WD & Kerbel, RS (2005).  Metronomic ABI-007: antiangiogenic and antitumor activity of a nanoparticle albumin-bound paclitaxel.  Poster Presentation at the AACR conference, Anaheim, CA.


    2004

  10. Ng, SSW, Gütschow, M, Eger, K & Figg, WD (2004).  Antitumor effects of thalidomide analogues in human prostate cancer xenografts implanted in immunodeficient mice.  Poster presentation at the AACR conference, Orlando, FL.


    2003

  11. Ng, SSW, Figg, WD & Sparreboom, A (2003).  Taxane-mediated antiangiogenesis: influence of formulation vehicles and binding proteins.  Poster presentation at the 14th NCI-EORTC-AACR conference, Boston, MA.

  12. MacPherson, GR., Ng. SSW, Hobaugh, SW, Gangi, LM & Figg, WD (2003).  Gene expression profiling of prostate cancer xenografts and human endothelial cells treated with thalidomide and thalidomide analogs.  Poster presentation at the AACR New Directions in Angiogenesis Research conference, Chicago, IL.

  13. Ng, SSW, Gütschow, M, Weiss, M, Hauschildt, S, Hecker, TK, Teubert, U, Luzzio, FA, Kruger, EA, Eger, K & Figg, WD (2003).  Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.  Poster presentation at the AACR conference, Washington, DC.

  14. Ng, SSW & Figg, WD (2003).  Antitumor activity of herbal supplements in human prostate cancer xenografts implanted in immunodeficient mice.  Poster presentation at the AACR conference, Washington, DC.

  15. Macpherson, GR, Ng, SSW, Forbes, S, Melillo, G, Karpova, T, McNally, J, Martinez, A, Cuttitta, F, Price, DK & Figg, WD (2003).  The anti-angiogenesis activity of endostatin is independent of HIF-1 activity.  Poster presentation at the AACR conference, Washington, DC.

  16. Lepper, ER, Ng, SSW, Gütschow, M, Weiss, M, Hauschildt, S, Hecker, TK, Teubert, U, Luzzio, FA, Kruger, EA, Eger, K & Figg, WD (2003).  Structure-activity relationship of thalidomide analogues for inhibition of angiogenesis.  Poster presentation at the AACR conference, Washington,  DC.


    2002

  17. Ng, SSW, Kruger, EA, Luzzio, FA, Eger, K, Guetschow, M, Hauschildt, S, Hecker, T, Teubert, U, Weiss, M & Figg, WD (2002).  In vitro antiangiogenic activity of thalidomide analogues.  Poster presentation at the 13th NCI-EORTC-AACR conference, Frankfurt, Germany.


    2000

  18. Ng, SSW, Tsao, MS & Hedley, DW (2000).  Inhibition of the phosphatidylinositide 3-kinase/protein kinase B cell survival pathway enhances gemcitabine toxicity in human pancreatic cancer cells.  Proc. AACR, 41: 71.  Oral presentation at the AACR conference, San Francisco, CA.

  19. Ng, SSW, Tsao, MS & Hedley, DW (2000).  The phosphatidylinositide 3-kinase inhibitor wortmannin blocks protein kinase B phosphorylation in orthotopic human pancreatic cancer xenografts in immunodeficient mice.  Poster presentation at the 11th NCI-EORTC-AACR conference, Amsterdam, the Netherlands.


    1999

  20. Ng, SSW, Tsao, MS & Hedley, DW (1999).  Inhibition of ras oncoprotein and receptor tyrosine kinases potentiates gemcitabine toxicity in human pancreatic adenocarcinoma cells.  Proc. Western Pharmacology Society, 42: 135.  Oral presentation at the Western Pharmacology Society conference, Maui, HI.


    1998

  21. Ng, SSW & Pang, CCY (1998).  Venous versus arterial actions of diethylamine/nitric oxide (DEA/NO) complex and S-nitroso-N-acetylpenicillamine (SNAP) in vivo.  Naunyn-Schmiedeberg's Archives of Pharmacology, 358 (Suppl. 1): R222.  Poster presentation at the XIIIth International Congress of Pharmacology, Munich, Germany.

  22. Ng, SSW & Pang, CCY (1998).  Zaprinast, a type V phosphodiesterase inhibitor, dilates capacitance vessels in anaesthetised rats.  Proc. Western Pharmacology Society, 41: 282.  Poster presentation at the Western Pharmacology Society Conference, Mazatlan, Mexico.

    23.  


Books (and Chapters)

 
Peer-Reviewed Papers | Conference Proceedings | Books (and Chapters)

 

        2008

  1. Syliva S.W. Ng and Kim N. Chi. Chapter 27: Surrogates for Clinical Development In: Angiogenesis: An integrated approach from science to medicine (2008).


    2002

  2. Macpherson, G.R., Ng, S.S.W., Lakhani, N.J., Price, D.K., Venitz, J. and Figg, W.D. . Antiangiogenesis therapeutic strategies in prostate cancer. In Cher, M.L. and Raz., A. (eds), Prostate Cancer: New Horizons in Research and Treatment, 317-330. Kluwer Academic Publishers, the Netherlands. (2002).

     

 

Back to Sylvia Ng 

Back to Main Page